中国网财经2月25日讯(记者 段思琦)2月23日，首都医科大学附属北京天坛医院正式启动阿利妥治疗急性缺血性卒中患者的有效性及安全性研——一项随机对照研究：Aleeto in Acute ISchemic Stroke：A RandomISed ...

The challenges of translating neuroprotective interventions with promising efficacy in animal studies into effective ...

forming the theoretical basis for many of the acute stroke therapies under study (Lees et al., 2006) as well as the rationale for intervening within a therapeutic time window following ischemic ...

The following is a summary of “Association between impaired brachial flow-mediated dilation and early neurological ...

The following is a summary of “Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion,” published in the February ...

TIA is an acute ischemic event in the brain that typically resolves within two to 15 minutes, often leaving no detectable ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the peer-reviewed ...

An update from Diamedica Therapeutics ( ($DMAC) ) is now available. On February 20, 2025, DiaMedica Therapeutics appointed Daniel J. O’Connor to ...

Despite upstream recanalization in acute ischemic stroke, it is now increasingly recognized that blood flow may fail to reach downstream tissue ...

DiaMedica Therapeutics (DMAC) announced the peer-reviewed publication entitled: “Recombinant human tissue kallikrein-1 for treating acute ...